ReviewDrugs2021
Efmoroctocog Alfa: A Review in Haemophilia A.
Review in Drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Boosting peptide half-life: enabling efficient generation of Fc-peptide conjugates.Chemical science · 2026Article
- Recombinant Protein Drugs: A 2025 Update.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Molecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering.Biophysica · 2026Article
- Pharmacological considerations for next-generation protein therapeutics in cardiovascular disease.The Journal of pharmacology and experimental therapeutics · 2025Review
- Recombinant Proteins: Evolution to their Therapeutic Potential.Protein and peptide letters · 2025Review
- Advances in biopharmaceutical products for hemophilia.iScience · 2024Review
- Transforming Hemophilia A Care: Insights into New Therapeutic Options.Life (Basel, Switzerland) · 2024Review
- Neonatal Presentation of Severe Hemophilia A: An Original Case Report and a Literature Review.Children (Basel, Switzerland) · 2024Article
- Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization.Blood research · 2024Article
- Congenital Haemostasis Disorders and Urology Surgery: Is It Safe?Journal of clinical medicine · 2024Article
- Engineering protein-based therapeutics through structural and chemical design.Nature communications · 2023Review
- Clinical and Surgical Experiences with Efmoroctocog Alfa in Pediatric Population with Hemophilia A.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisObservational
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efmoroctocog alfa (Elocta
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.